Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-07
2010-10-12
Helms, Larry R. (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S184100, C424S277100
Reexamination Certificate
active
07811983
ABSTRACT:
Mutant LIGHT expressed in a tumor environment elicited high levels of chemokines and adhesion molecules, accompanied by massive infiltration of naïve T lymphocytes. Methods and compositions to elicit immune responses against tumors including tumor volume reduction and eradication of metastasis using mutant LIGHT are disclosed.
REFERENCES:
patent: 4797368 (1989-01-01), Carter et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5994523 (1999-11-01), Kawakami et al.
patent: 6048551 (2000-04-01), Hilfinger et al.
patent: 6140467 (2000-10-01), Ware
patent: 6207147 (2001-03-01), Hiserodt et al.
patent: 6475986 (2002-11-01), Aggarwal
patent: 6635743 (2003-10-01), Ebner et al.
patent: 7118742 (2006-10-01), Ware
patent: 7241576 (2007-07-01), Aggarwal
patent: 2003/0166546 (2003-09-01), Aggarwal
patent: 2005/0025754 (2005-02-01), Fu
patent: 2009/0093429 (2009-04-01), Fu et al.
patent: WO 00/53223 (2000-09-01), None
patent: WO 01/79496 (2001-10-01), None
patent: WO 02/32463 (2002-04-01), None
patent: WO 02/34780 (2002-05-01), None
patent: WO 03/040307 (2003-05-01), None
patent: WO 2008/098183 (2008-08-01), None
Yu et al , Nature Immunology, vol. 5, p. 141-149, Jan 4, 2004.
Tamada et al, Nature Medicine, vol. 6, p. 283-289, 2000, IDS filed Jan. 11, 2007, BF.
Harrop et al, J Biol Chem, vol. 273, p. 27548-27556, 1998.
MeSH word search results for LIGHT, fibrrosarcoma and L1210 cell (2009).
Sequence search result (2009).
Sequence search result -2 (2009).
MeSH word search results for fibrrosarcoma (2009).
MeSH word search results for L1210 cell (2009).
Database WPI (2002): “Section Ch, Week 200203,” Derwent Publications Ltd., Longdon, GB, AN 2002-026029 (WO01/79496-Abstract).
Database WPI (2003): “Section Ch, Week 200340,” Derwent Publications Ltd., Longdon, GB, AN 2003-430659 (WO03/040307-Abstract).
International Search Report issued in PCT/US2004/018631 (2004).
Boon et al., “Human tumor antigens recognized by T. lymphocytes,”J. Exp. Med., 183: 725-729 (1996).
Cannon et al., “Induction of transgene expression in Tg.AC(v-HA-ras) transgenic mice concomitant with DNA hypomethylation,”Mol Carcinog., 21: 244-250 (1998).
Chen et al., “Constiunulation of T cells for tumor immunity,”Immunol Today, 14: 483-486 (1993).
Cyster, “Chemokines and cell migration in secondary lymphoid organs,”Science, 286: 2098-2102 (1999).
Dougall et al. “RANK is essential for osteoclast and lymph node development,”Genes Dev, 13: 2412-2424 (1999).
Ettinger, “The Role of tumor necrosis factor and lymphotoxin in lymphoid organ development,”Curr Top Microbiol Immunol, 251: 203-210 (2000).
Fu et al., “Development and maturation of secondary lymphoid tissues,”Annu Rev Inununol,17: 399-433 (1999).
Kang, et al, “Signaling via LTbetaR on the lamina propria stromal cells of the gut is required for IgA production,”Nat Immunol, 3: 576-582 (2002).
Kim et al., “Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE,”J Exp Med, 192: 1467-1478 (2000).
Kong et al., “Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand,”Nature, 402: 304-309 (1999).
Leder, et al., “v-HA-ras transgene abrogates the initiation step in mouse skin tumorgenesis: effects of phorbol esters and terinoic acid,”Proc. Natl. Acad. Sci. USA, 87: 9178-9182 (1990).
Mauri et al., “LIGHT, a new member of TNF superfamily, and lymphotoxin alpha are ligands for herpes virus entry mediator,”Immunity, 8:21-30 (1998).
Melero et al., “Monoclonal antibodies against the 4-1BB T0cell activation molecule eradicate established tumors,”Nat Med, 3: 682-685 (1997).
Ochsenbein et al., “Roles of tumor localization, second signals and cross priming in cytotoxic T-cell induction,”Nature, 411: 1058-1064 (2001).
Ostrand-Rosenberg, “Cell-based vaccines for the stimulation of immunity to metastatic cancers,”Immunol Rev, 170: 101-114 (1991).
Peace et al., “Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated rats peptide,”J Exp Med, 179: 473-479 (1994).
Rooney et al., “The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells,”J Biol Chem, 275: 14307-14315 (2000).
Rosenberg, et al., “Progress in human tumor immunology and immunotherapy,”Nature, 411: 380-384 (2001).
Ruddle, “Lymphoid neo-organeogenesis: lymphotoxin's role in inflammation and development,”Immuno Res, 19: 119-125 (1999).
Sarma et al., “Cytotoxic T lymphocytes to an unmutated tumor rejection antigen PIA: normal development but restrained effector function in vivo,”J Exp Med, 189: 811-820 (1999).
Schreiber, “Tumor Immunology,” In:Fundamental Immunology(ed. Paul, W.E.) Lippincott Rave Press, New York, 1247-1280 (1999).
Sha et al., “Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice,”Nature, 335: 271-274 (1988).
Tamada et al., “Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway,”Nat Med, 6: 283-289 (2000).
Wang et al., “The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function,”Eur J Immunol, 32: 1969 (2002).
Wang et al., “The regulation of T cell homeostasis and autoimmunity by T cell derived LIGHT,”J clinic. Invest, 108: 1771-1780 (2001).
Wick et al., “Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy,”J Exp Med, 186. 229-238 (1997).
Wu et al., “The requirement of membrane lymphotoxin for the presence of dendritic cells in lymphoid tissues,”J Exp Med, 190: 629-638 (1999).
Ye et al., “Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival”J Exp Med, 195: 795-800 (2002).
Ye et al., “Gene therapy for cancer using single-chain Fv fragments specific for 4-IBB,”Nat Med, 8: 343-348 (2002).
Zhai et al., “LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer,”Journal of Clinical Investigation, 102: 1142-1151 (1998).
Zinkernagel, “Immunity against solid tumors?,”Int J Cancer, 93: 1-5 (2001).
Fan et al., “NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors,”Blood, 107: 1342-1351 (2006).
Fidler, “The pathogenesis of cancer metastasis: the seed and soil hypothesis revisited,”Nature Reviews Cancer, 3: 453-458 (2003).
Ghobrial et al., “Targeting Apoptosis Pathways in Cancer Therapy,”CA Cancer J. Clin., 55 (3): 178-194 (2005).
Houghton, “LIGHTing the way for tumor immunity,”Nature Immunology, 5(2): 123-124 (2004).
Koscielny et al., “Breast Cancer: Relationship between the size of the primary tumour and the probability of metastatic dissemination,”Br. J. Cancer, 49: 709-715 (1984).
Koscielny et al., “A simulation model of the natural history of human breast cancer,”Br. J. Cancer, 52: 515-524 (1985).
Mezhir et al., “Ionizing radiation: a genetic switch for cancer therapy,”Cancer Gene Therapy, 13: 1-6 (2006).
Rosenberg et al., “Cancer immunotherapy: moving beyond current vaccines,”Nature Medicine, 10(9): 909-915 (2004).
Rosenberg et al., “Shedding Light on Immunotherapy for Cancer,”The New England Journal of Medicine, 350(14): 1461-1463 (2004).
Schneider et al., “Lymphotoxin and LIGHT signaling pathways and target genes,&#x
Barnes & Thornburg LLP
Helms Larry R.
Martin Alice O.
The University of Chicago
Yao Lei
LandOfFree
Increased T-cell tumor infiltration and eradication of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Increased T-cell tumor infiltration and eradication of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Increased T-cell tumor infiltration and eradication of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4234170